smart city tech

City of Houston partners with digital waste, recycling solutions company

Mayor Sylvester Turner says this new smart city technology partner will help digitize and optimize waste operations. Photo via rubicon.com

The City of Houston announced that it has entered into a three-year partnership with Kentucky-based Rubicon with the goal of improving its waste, recycling, and heavy-duty municipal fleet operations.

According to a statement, the city has installed the company's RUBICONSmartCity platform on the Solid Waste Management Department’s 391 vehicles, and has trained the workforce on using the SaaS software.

“Partnering with Rubicon will help our great city optimize its solid waste operations and make it possible for us to digitize our entire waste and recycling management system,” Mayor Sylvester Turner said in a statement. “The City of Houston is committed to providing the highest level of service to its residents and this partnership will allow us to provide better services, save taxpayer dollars, and deliver a better quality of life for Houstonians.”

RUBICONSmartCity is a cloud-based suite that will allow the department's workforce to track key metrics about pickup, including issues at the curb and recycling contamination, as well as information about its fleet of vehicles. The platform includes a mobile app, an onboard data collection device, and a web-based portal.

The city envisions that information collected by RUBICONSmartCity will enhance reporting tools used by 311 and give the department a better understanding of what's happening in the field.

“The City’s Department of Solid Waste can use this information to advise and educate residents around service scheduling, best practices for waste and recycling management, and reduce costly return trips,” Solid Waste Management Department Director Mark Wilfalk said in a statement. “These insights, alongside route optimization and digitization efforts, are set to deliver an optimal operation to the City of Houston.”

RUBICONSmartCity is used in more than 70 cities across the U.S., including San Antonio. The product was the focus of a 2021 Amazon documentary entitled "The Road to Zero Waste," which focused on Rubicon's work in Santa Fe, New Mexico.

“Our partnership with the City of Houston is off to a fantastic start, as we were able to install our products and train the entire Solid Waste Department’s workforce in only 73 days, an incredibly fast turn for such an undertaking,” Michael Allegretti, Chief Strategy Officer at Rubicon, said in a statement. "This partnership comes at a critically important time, as Houston and other cities across the nation look to maintain, and ultimately expand, service levels.”

In August 2021, the City of Houston also launched HTX Collects, a mobile app aimed at helping residents keep track of weekly services, updates, and waste collection days. At that time, the city estimated that it collected curbside service for over 395,000 residential homes within the city limits.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted